ABSTRACT-
Calcium channel blockers are mainly divided into three types, namely, 1,4-dihydropyridine, phenylalkylamine and benzothiazepine types, from their structure (1). Lomerizine, 1-[bis(4-fluorophenyl)methyl]-4-(2,3,4 trimethoxybenzyl)piperazine dihydrochloride has been reported to inhibit [3H]nitrendipine binding to synapto some membranes in guinea pig cerebral cortex (2) and canine aorta (3), to inhibit the voltage-gated Ca 2+ current in rat hippocampal pyramidal neurons (4) and to reduce the number of migraine attacks in patients with migraine (5, 6). Thus, lomerizine is regarded as a new class of cal cium channel blocker with different structure from the representative calcium channel blockers as described the above. However, the pharmacological profile of lomeri zine has not yet been fully clarified in comparison with that of existing calcium channel blockers. Therefore, we investigated the effect of lomerizine on the Ba2+ current through the voltage-gated Ca 2+ channel in rat pheochromocytoma (PC12) cells and compared it with those of various other types of calcium channel blockers and that of dimetotiazine, an anti-migraine drug.
PC 12 cells (Riken Cell Bank, Ibaraki) were prepared as previously described (7). In brief, PC12 cells were cul tured in Dulbecco's Modified Eagle's Medium (Nikken Bio Medical, Kyoto) containing 7° fetal bovine serum (Moregate, Melbourne, Australia), 7% heat-inactivated horse serum (Gibco, Grand Island, NY, USA), 2 MM L glutamine (Wako, Osaka) and 50 pg/ml gentamicin sul fate (Wako) at 37C in an atmosphere of 5% CO2. They were then plated onto collagen-coated glass slides. After an additional 2 to 3 days in culture, the cells were used for the following experiments.
Membrane potentials and currents were measured using whole-cell recordings and improved patch-clamp techniques (8) . The cells were continuously superfused with an extracellular solution containing 140 mM NaCI, 5.4 mM KCI, 1. Membrane currents were acquired on-line and analyzed later by a computer (PC-5/120; Inter Medical, Nagoya) using pCLAMP6 software (Axon). As Ca 2+ channels are more permeable to Ba2+ than to Ca 2+ (9), extracellular CaC12 was replaced with BaC12 (10.8 mM) to obtain a large inward Ba2+ current permeating through voltage gated Ca2+ channels. Compensation was made for series resistance, and electrical signals were filtered at 5 kHz. The inward current was activated by a depolarizing step to +10 mV from a holding potential of 60 mV. The experiments were performed at approximately 361C using a TC2b;p bipolar temperature controller (Bioptechs, Inc., Butler, PA, USA). The IC50 value for each drug in in hibiting Ba2+ current was calculated by Probit analysis.
Lomerizine 2HC1 (Kanebo, Osaka); nicardipine HC1 flunarizine 2HCl, (±)-verapamil, diltiazem HCl (Sigma, St. Louis, MO, USA); and dimetotiazine mesylate (Shionogi, Osaka) were first dissolved in dimethyl sulf oxide (DMSO, Wako) and added to extracellular solu tions so that the final concentration of DMSO was <<0.1%. it was first observed at 20 sec after the start of the superfusion, and a steady-state blockade was obtained by 60 sec after the start of the superfusion (Fig. 1A) at concentrations of 0.1-10 ,uM. This effect was similar to those produced by nicardipine, flunarizine and dimetotiazine (data not shown). On the other hand, the steady-state blocking effect of diltiazem reached a steady state level at 120 sec after the start of the superfusion at concentrations of 1-100 ,uM in most of the cells examined (Fig. 1B) . The profile of the inhibition produced by verapamil was simi lar to that seen with diltiazem (data not shown). There fore, for routine assessment of the typical inhibition produced by each drug and to derive the concentration inhibition curves, the effects on the Ba2+ current of lomerizine, nicardipine, flunarizine and dimetotiazine in concentrations of 0.1-10 ,uM were tested at 60 sec after the beginning of their superfusion, whereas the effects of diltiazem and verapamil in concentrations of 1-100 ,uM were tested at 120 sec. Figure 2 shows typical examples of the inhibitory effects of lomerizine, nicardipine, flunarizine, diltiazem, verapamil and dimetotiazine on the Ba2+ current. Cur rent traces obtained just before (Control) and after the (3.1 52), 13.0 (6.7 27) and 10.4 (5.1 21) pM, respec tively. Dimetotiazine produced only an approximately 40% inhibition at a concentration of 10 pM (the highest concentration used). Lomerizine and nicardipine were both > 4 times more potent than the other three calcium channel blockers and dimetotiazine. We examined the effect of lomerizine on Ca2+ channels in PC12 cells and compared the effect with those of four other calcium channel blockers and with that of dimetotiazine. PC12 cells have been used widely in studies requiring a neuron-like clone cell-line. The Ba2+ current in PC12 cells was classified as an example of L-type Ca 21 channel activity by Tsien et al. (11) . Although un differentiated PC 12 cells express predominantly L-type channels, recently they have been reported to possess an N-type and c)-agatoxin-IVA-sensitive (P/Q-type) compo nent, but not the T-type (12, 13) . However, the ex perimental condition (-60 mV holding potential) in the present study is suitable for detecting L-type, but not N or T-type (11), Ca 21 channel activity. Lomerizine inhibits both L-type and T-type Ca 2+ currents in a hippocampal CA1 pyramidal single neuron (4) and does not have any affinity for N-type Ca2+ channels in a [1211]w-conotoxin binding study using rat cortical membranes (unpublished observation, H. Hara et al.).
In this experiment, lomerizine concentration-depend ently inhibited high-voltage activated inward Ba2+ cur rents. The time course (inhibition pattern) of the effect of lomerizine on Ba2+ current was similar to those of nicardipine and flunarizine, but different from those of diltiazem and verapamil. Maximal steady state inhibition induced by lomerizine, nicardipine or flunarizine was ob served faster than that induced by diltiazem or verapamil. These data indicate that the mode of action of lomerizine in inhibiting L-type Ca 2+ channels may be similar to that of nicardipine and flunarizine and different from that of diltiazem and verapamil.
Each of the 1,4-dihydropyridines studied here, diltia zem and verapamil, interacts with a specific receptor domain found on a large (about 165 kD) membrane spanning protein that constitutes a substantial portion of the L-type, voltage-gated Ca 2+ channel (14) . The 1,4 dihydropyridine receptor is located on the surface of the channel; on the other hand, the diltiazem and verapamil binding sites are located internally, deep within the chan nel. Lomerizine has been supposed to bind to the 1,4-di hydropyridine binding site from the results obtained by a
[3H]nitrendipine binding study using synaptosome mem branes in guinea pig cortex (2). These different locations of the binding sites of the drugs may explain the different time course of the inhibition of Ba2+ current among the drugs tested in the present experiment.
The potencies of lomerizine and other calcium channel blockers tested in inhibiting the Ba2+ currents through the high voltage-activated Ca 21 channels were in the follow ing order: lomerizine = nicardipine > flunarizine > verap amil > diltiazem > dimetotiazine.
Although the order obtained with lomerizine and flunarizine are well-consis tent with that obtained by a [3H]nitrendipine binding study (2), the inhibitory effect of nicardipine in this ex periment was somewhat weaker than that expected from the binding study. Nicardipine was about 30 times more potent than lomerizine in inhibiting [3H]nitrendipine binding to synaptosome membranes in guinea pig cortex. Nicardipine has been reported to suppress the L-type Ca2+ channel current found in PC12 cells with an IC50 value of 2.7 pM (12) . The IC50 value for nicardipine in PC12 cells is consistent with that reported here (2 pM). The inhibitory effect of 1,4-dihydropyridine derivatives such as nicardipine on the Ba2+ currents through the high-voltage activated Ca2+ channels has been reported to be weaker in neuronal cells than in other cells such as cardiac cells and smooth muscle cells (15, 16 Lomerizine has been reported to preferentially inhibit T-type Ca2+ channels rather than L-type Ca2+ channels in rat pyramidal cells (4). The profile of lomerizine resem bled that of flunarizine (4). Furthermore, the effect of lomerizine on the Ba2+ currents in the present study was also similar to that of flunarizine. The similarity be tween lomerizine and flunarizine may be due to the com mon diphenylpiperazine structure.
Lomerizine has shown to reduce the number of migraine attacks in patients with migraine (5). Flunarizine and nicardipine have been reported to show better thera peutic effects than the placebo in double-blind and placebo-controlled clinical trials in migraine patients (17, 18) . The beneficial effects of lomerizine in migraine patients are supposed to mainly result from the anti vasoconstrictor effect and inhibitory effect on spreading depression by suppression of L-type Ca2+ channels in smooth muscle and neuronal cells, respectively (6). Taken together, the data in the present study and the above findings indicate that the mechanism of the anti-migraine effect of lomerizine may be similar to those of flunarizine and nicardipine from the viewpoint of the inhibitory effects on L-type Ca2+ channels. Further studies are needed to clarify the mechanism.
